IN2013MN01519A - - Google Patents

Download PDF

Info

Publication number
IN2013MN01519A
IN2013MN01519A IN1519MUN2013A IN2013MN01519A IN 2013MN01519 A IN2013MN01519 A IN 2013MN01519A IN 1519MUN2013 A IN1519MUN2013 A IN 1519MUN2013A IN 2013MN01519 A IN2013MN01519 A IN 2013MN01519A
Authority
IN
India
Prior art keywords
pharmaceutically acceptable
acceptable salt
diaminopyrimidine derivative
delayed
gastroparesis
Prior art date
Application number
Other languages
English (en)
Inventor
Hyun Joo Lee
Dong Hoon Kim
Tae Kyun Kim
Young Ae Yoon
Jae Young Sim
Myung Hun Cha
Eun Jung Jung
Kyoung Kyu Ahn
Tai Au Lee
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of IN2013MN01519A publication Critical patent/IN2013MN01519A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN1519MUN2013 2011-02-25 2012-02-24 IN2013MN01519A (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110016981 2011-02-25
PCT/KR2012/001423 WO2012115478A2 (en) 2011-02-25 2012-02-24 Diaminopyrimidine derivatives and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
IN2013MN01519A true IN2013MN01519A (de) 2015-06-12

Family

ID=46721361

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1519MUN2013 IN2013MN01519A (de) 2011-02-25 2012-02-24

Country Status (18)

Country Link
US (4) US9890138B2 (de)
EP (2) EP2678332B1 (de)
JP (2) JP5890436B2 (de)
KR (2) KR101671341B1 (de)
CN (2) CN103402997B (de)
AU (2) AU2012221927B2 (de)
BR (2) BR112013020641B1 (de)
CA (2) CA2827030C (de)
DK (1) DK2678332T3 (de)
ES (2) ES2587304T3 (de)
HK (2) HK1188215A1 (de)
HU (1) HUE029988T2 (de)
IN (1) IN2013MN01519A (de)
MX (2) MX337477B (de)
PL (2) PL2678332T3 (de)
PT (1) PT2678332T (de)
RU (1) RU2587493C2 (de)
WO (2) WO2012115478A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012115478A2 (en) * 2011-02-25 2012-08-30 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
KR102455889B1 (ko) 2012-11-21 2022-10-17 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
KR101657616B1 (ko) * 2013-05-24 2016-09-19 주식회사유한양행 피리미딘 고리를 포함하는 바이사이클릭 유도체 및 그의 제조방법
NZ748260A (en) * 2013-08-30 2020-01-31 Ptc Therapeutics Inc Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN104003944B (zh) * 2014-05-29 2016-08-24 西北师范大学 一种嘧菌胺的制备方法
PL3207035T3 (pl) * 2014-10-13 2020-06-01 Yuhan Corporation Związki i kompozycje do modulowania aktywności zmutowanych kinaz EGFR
US10300155B2 (en) 2015-12-31 2019-05-28 Washington University Alpha-synuclein ligands
CN105646321A (zh) * 2016-01-07 2016-06-08 中国药科大学 (s)-3-羟基吡咯烷盐酸盐的制备方法
GB201604647D0 (en) 2016-03-18 2016-05-04 Mission Therapeutics Ltd Novel compounds
KR102441327B1 (ko) * 2018-05-18 2022-09-07 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 산부가염의 신규의 제조방법
EP3836932A2 (de) 2018-08-17 2021-06-23 PTC Therapeutics, Inc. Verfahren zur behandlung von bauchspeicheldrüsenkrebs
MX2021007192A (es) * 2018-12-18 2021-07-21 Astrazeneca Ab Proceso farmaceutico e intermedios.
CN110317176A (zh) * 2019-07-04 2019-10-11 沈阳药科大学 2-氨基嘧啶类化合物及其用途
KR20220006776A (ko) * 2020-07-09 2022-01-18 주식회사유한양행 다이아미노피리미딘 유도체 또는 이의 약학적으로 허용가능한 염을 포함하는 약학 조성물 및 이의 제조방법

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
CZ284687B6 (cs) 1986-04-30 1999-02-17 Dainippon Pharmaceutical Co., Ltd. Substituovaný benzamidový derivát, způsob jeho výroby a farmaceutický prostředek na jeho bázi
GB9005014D0 (en) 1990-03-06 1990-05-02 Janssen Pharmaceutica Nv N.(4.piperidinyl)(dihydrobenzofuran or dihydro.2h.benzopyran)carboxamide derivatives
HUT64023A (en) 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
CZ101496A3 (en) * 1993-10-12 1996-11-13 Du Pont Merck Pharma N-alkyl-n-aryl-pyrimidinamines and derivatives thereof
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
IL112024A (en) * 1993-12-21 1999-07-14 Novo Nordisk As Pharmaceutical compositions comprising tetrahydropyridine derivatives substituted with oxadiazole or thiadiazole for treating gastrointestinal motility disorders
US5750531A (en) 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
US5739151A (en) * 1996-07-19 1998-04-14 Sepracor Inc. Method for treating emesis and central nervous system disorders using optically pure (+) norcisapride
IN188411B (de) 1997-03-27 2002-09-21 Yuhan Corp
US6825198B2 (en) * 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
MXPA06000771A (es) 2003-07-25 2006-04-18 Ciba Sc Holding Ag Uso de 2,4-bis(alquilamino)-pirimidinas o -quinazolinas substituidas como antimicrobianos.
AU2004268641A1 (en) * 2003-08-29 2005-03-10 Dynogen Pharmaceuticals, Inc. Compositions useful for treating gastrointestinal motility disorders
US20060057972A1 (en) 2004-09-14 2006-03-16 Wikel Harold L Adapter for a modular wireless communication device
US20060128726A1 (en) 2004-11-24 2006-06-15 Xuebao Wang Process for preparing novel crystalline forms of (2S)-1-[[(7R)-7-(3,4-dichlorophenyl)-4,7-dihydro-5-methylpyrazolo[1,5]pyrimidine-6-yl]carbonyl]-2-(4-fluorophenyl)pyrrolidine, novel stable forms produced therein and formulations
CA2598516C (en) 2005-02-25 2010-05-11 Pfizer Inc. Benzisoxazole derivatives
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007062417A1 (en) * 2005-11-28 2007-05-31 Kalypsys, Inc. Methods of preparing 2-imidazol-1-yl-4-methyl-6-pyrrolidin-2-yl-pyrimidine and 4-(1-alkylpyrrolidin-2-yl)-2-(1h-imidazol-1-yl)-6-methylpyrimidine derivatives
WO2007114323A1 (ja) * 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
US20090306067A1 (en) 2006-04-10 2009-12-10 Harald Engelhardt 2, 4-diaminopyrimidide derivates and their use for the treatment of cancer
WO2008114378A1 (ja) * 2007-03-19 2008-09-25 Fujitsu Limited データ処理装置、そのデータ監視方法、そのデータ監視プログラム、及びそのデータ監視プログラムを格納した記録媒体
CN101952275B (zh) * 2008-02-22 2014-06-18 弗·哈夫曼-拉罗切有限公司 β-淀粉样蛋白的调节剂
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
WO2012115478A2 (en) * 2011-02-25 2012-08-30 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof

Also Published As

Publication number Publication date
MX337477B (es) 2016-03-07
CN103391935B (zh) 2015-12-23
WO2012115480A3 (en) 2012-10-18
CA2827072A1 (en) 2012-08-30
CA2827072C (en) 2019-01-08
US20130331377A1 (en) 2013-12-12
CA2827030A1 (en) 2012-08-30
US20180072705A1 (en) 2018-03-15
AU2012221927B2 (en) 2016-04-28
KR101671341B1 (ko) 2016-11-01
US20180111918A1 (en) 2018-04-26
JP2014506591A (ja) 2014-03-17
CN103402997A (zh) 2013-11-20
HK1188214A1 (zh) 2014-04-25
PT2678332T (pt) 2016-08-22
MX2013009627A (es) 2014-02-17
JP2014506592A (ja) 2014-03-17
JP5980236B2 (ja) 2016-08-31
AU2012221925B2 (en) 2016-05-05
CA2827030C (en) 2019-01-08
RU2013142188A (ru) 2015-03-27
US9890138B2 (en) 2018-02-13
WO2012115480A2 (en) 2012-08-30
ES2587304T3 (es) 2016-10-21
DK2678332T3 (en) 2016-08-15
JP5890436B2 (ja) 2016-03-22
CN103402997B (zh) 2015-08-26
RU2587493C2 (ru) 2016-06-20
BR112013020641A2 (pt) 2016-10-18
HK1188215A1 (en) 2014-04-25
BR112013019942B1 (pt) 2022-01-11
EP2678331A2 (de) 2014-01-01
EP2678332B1 (de) 2016-05-18
HUE029988T2 (en) 2017-04-28
US9850227B2 (en) 2017-12-26
CN103391935A (zh) 2013-11-13
EP2678331A4 (de) 2014-07-30
MX2013009549A (es) 2013-09-06
EP2678331B1 (de) 2016-04-27
US10227330B2 (en) 2019-03-12
WO2012115478A3 (en) 2012-10-18
KR20120098484A (ko) 2012-09-05
BR112013019942A2 (pt) 2018-08-14
PL2678332T3 (pl) 2016-12-30
US20150274700A2 (en) 2015-10-01
EP2678332A2 (de) 2014-01-01
US10640490B2 (en) 2020-05-05
WO2012115478A2 (en) 2012-08-30
ES2579830T3 (es) 2016-08-17
EP2678332A4 (de) 2014-07-23
MX336155B (es) 2016-01-07
US20130338179A1 (en) 2013-12-19
PL2678331T3 (pl) 2016-12-30
KR101671348B1 (ko) 2016-11-01
KR20120098483A (ko) 2012-09-05
BR112013020641B1 (pt) 2021-11-03
RU2013142187A (ru) 2015-03-27

Similar Documents

Publication Publication Date Title
IN2013MN01519A (de)
WO2012115479A3 (en) Diaminopyrimidine derivatives and processes for the preparation thereof
CN112074519A8 (zh) 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
IL214572A (en) Annals of 9 - Alkylaryl - 9h - Furin - 6 - Converted Illamine, a Pharmaceutical Composition Containing Them and These Compounds That Are a Toll-like Colton Antagonist for the Treatment of Disease
WO2006104826A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA201290394A1 (ru) Морфолинотиазолы в качестве позитивных аллостерических модуляторов альфа 7
WO2007136577A3 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
TNSN07313A1 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
DK1695710T3 (da) Krystallinsk betad-form af ivabradinhydrochlorid, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende denne
HK1120442A1 (en) Novel opioid antagonists
CL2007003266A1 (es) Compuestos derivados de progesterona, antagonistas del receptor de progesterona; composicion farmaceutica; y uso para el tratamiento de endometriosis, miomas o tumores dependientes de hormonas.
EP4268814A3 (de) Pharmazeutische zusammensetzung zur behandlung des trockenen auges
MX340234B (es) Tratamiento para transtornos gastrointestinales.
MX2014001798A (es) Tratamientos para trastornos gastrointestinales.
UA100877C2 (ru) Замещенные спироциклические производные пиперидина как лиганды рецепторов гистамина-3 (h3)
CL2011000061A1 (es) Compuestos derivados de tetrahidrocinolinas, inhibidores de la 11-beta-hsd1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la diabetes, obesidad, trastornos de ingestion de comida o dislipidemia.
WO2010031521A3 (en) Pancreatic polypeptide and variants thereof for use in the treatment of intestinal disorders
WO2011045232A3 (en) Neuropeptide-2 receptor (y-2r) agonists
EP2238105A4 (de) Neuartige verbindungen, isomer daraus oder pharmazeutisch akzeptable salze davon als vanilloid-rezeptorantagonisten sowie pharmazeutische zusammensetzungen damit
WO2014016754A3 (en) Pharmaceutical compositions of proton pump inhibitor
EA201171271A1 (ru) Фармацевтическая композиция в форме частиц с опиоидом и антагонистом опиоида
UA112764C2 (uk) Оптимізований синтез чистих, неполіморфних кристалічних жовчних кислот із заданим розміром частинок
PT1861360E (pt) Derivados de pirrolidina como antagonistas de receptores h3 de histamina